A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors

Antiviral Research

Volumn 41, Issue 1, 1999, Pages 35-43

  Bedard, Jean ^a   May, Suzanne ^a   Barbeau, Dominique ^a   Yuen, Leonard ^a   Rando, Robert F ^a   Bowlin, Terry L ^a  

^a Shire Canada   (Canada)

Author keywords

Cell viability; Colorimetric assay; Cytomegalovirus; DHPG; HPMPC

Indexed keywords

CIDOFOVIR; GANCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NEWBORN; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; COLORIMETRY; CYTOMEGALOVIRUS; CYTOPATHOGENIC EFFECT, VIRAL; CYTOSINE; FIBROBLASTS; GANCICLOVIR; HUMANS; MICROBIAL SENSITIVITY TESTS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; TETRAZOLIUM SALTS; VIRUS REPLICATION;

EID: 0033083487     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00061-8     Document Type: Article

References (20)

1. Alford, C.A., Britt, W.J., 1993. Cytomegalovirus. In: Roizman, B., Whitley, R.J., Lopez, C. (Eds.), The Human Herpesviruses. Raven Press, New York, pp. 227-255.
2. Causey, D., 1991. Concomitant ganciclovir and zidovudine treatment for cytomegalovirus retinitis in patients with HIV infection: An approach to treatment. J. Acquired Immune Defic. Syndr. 4, S16-S21.
3. Chou, S., Erice, A., Jordan, M.C., Vercellotti, G.M., Michels, K.R., Talarico, C.L., Stanat, S.C., Biron, K.K., 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. Infect. Dis. 171, 576-583.
4. Collaborative DHPG Treatment Study Group, 1986. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N. Engl. J. Med. 27, 801- 805.
5. Dankner, W.M., Scholl, D., Stanat, S.C., Martin, M., Sonke, R.L., Spector, S.A., 1990. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28, 293-298.
6. Dicker, I.B., Blasecki, J.W., Seetharam, S., 1995. Herpes simplex type 1: LacZ recombinant viruses. II Microtiter plate-based colorimetric assays for the discovery of new antiherpes agents and the points at which such agents disrupt the viral replication cycle. Antiviral Res. 28, 213-224.
7. Gadler, H., 1983. Nucleic acid hybridization for measurement of effects of antiviral compounds on human cytomegalovirus DNA replication. Antimicrob. Agents Chemother. 24, 370- 374.
8. Hanson, M.N., Preheim, L.C., Chou, S., Talarico, C.L., Biron, K.K., Erice, A., 1995. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39, 1204-1205.
9. Hippenmeyer, P.J., Dilworth, V.M., 1996. A rapid assay for determination of antiviral activity against human cytomegalovirus. Antiviral Res. 32, 35-42.
10. Jacobson, M.A., Drew, W.L., Feinberg, J., O'Donnell, J.J., Whitmore, P.V., Miner, R.D., Parenti, D., 1991. Foscarnet therapy for ganciclovir resistant cytomegalovirus retinitis in patients with AIDS. J. Infect. Dis. 163, 1348-1351.
11. Jacobson, M.A., 1997. Ganciclovir therapy for severe cytomegalovirus infection in immunocompetent patients. Clin. Infect. Dis. 25, 1487-1488.
12. th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC Abstract H65.
13. Lewis, A.F., Drach, J.C., Fennewald, S.M., Huffman, J.H., Ptak, R.G., Sommadossi, J-P., Revankar, G.R., Rando, R.F., 1994. Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo [4,5-d] pyrimidine ring system. Antimicrob. Agents Chemother. 38, 2889-2895.
14. McLaren, C., Ellis, M.N., Hunter, G.A., 1983. A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. Antiviral Res. 3, 223- 234.
15. Musiani, M., Zerbini, M., Gentilomi, G., La Placa, M., 1988. Rapid quantitative assay of cytomegalovirus infectivity. J. Virol. Methods 20, 333-340.
16. Palestine, A.G., Polis, M.A., DeSmet, M.D., Baird, B.F., Falloon, J., Kovacs, J.A., Davey, R.T., Zurlo, J.J., Zunich, K.M., Davis, M., et al., 1991. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 115, 665-673.
17. Smith, I.L., Cherrington, J.M., Jiles, R.E., Fuller, M.D., Freeman, W.R., Spector, S.A., 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176, 69-77.
18. Stanat, S.C., Reardon, I.E., Erice, A., Jordan, M.C., Drew, W.L., Biron, K.K., 1991. Ganciclovir-resistant cytomegalovirus clinical isolates: Mode of resistance to ganciclovir. Antimicrob. Agents Chemother. 35, 2191-2197.
19. Stinski, M.F., 1990. Cytomegalovirus and its replication. In: Fields, B.N., Knipe, D.M., et al. (Eds.), Virology, 2nd Ed. Raven Press, New York, pp. 1959-1980.
20. Tatarowicz, W.A., Lurain, N.S., Thompson, K.D., 1991. In situ ELISA for the evaluation of antiviral compounds effective against human cytomegalovirus. J. Virol. Methods 35, 207-215.